Note: Descriptions are shown in the official language in which they were submitted.
1 30~653
An antihepatopathic composition
The present invention relates to a novel antihepato-
pathic composition comprising protoporphyrin IX-zinc(II)
complex as an active ingredient.
The liver, which is the largest single organ of
the body, plays a central role in the metabol i sm in the
body and its functions are widely varied, including the
m~tabolism of various substances, detoxication, production
of bilirubin, secretion of bile, and so on. These func-
tions may be impaired, acutely or chronically, by various
factors such as poisons, drugs, alcohol, viruses, mal-
nutrition, radiation, cholestasis, and so on and such
impairments are manifested as alcoholic liver disorder,
viral hepatitis, drug-induced liver disease, hepatic
disorder associated with cholestasis, fatty liver, jaun-
dice and oth~r diseases. Where the impairments are long-
sustained, hepatocirrhosis and even liver cancer may
ensure. In treating these hepatopathies, repair of the
injured liver tissue and improvement of the decreased
function of the liver are acknowledged to be essential.
However, in the absence of a satisfactory livcr function-
improving agent, the current therapeutic regimen consists
basically of a diet therapy using high-calorie and high
protein diets and rest treatment, and the administration
of liver protecting drugs is superimposed thereon.
'"'~)
1 30~653
-- 2
As a drug o~ this purpose, protoporphyrin disodium
has been employed but no sufficient antihepatopa-thic
effect can be expected of this drug. The use of immno-
potentiators such as interferons has also been attempted
but these drugs have the disadvantage that they cause
strong side effects and tha-t it takes a long time for
their efficacies to be evaluated.
On the other hand, protoporphyrin IX-zinc(II) com-
plex is a known compound and it is also known that the
heme oxygenase activity of neotanal rat is inhibi-ted
by subcutaneous or intraperitoneal administration [Bio-
chimica et Biophysica Acta, 673 (1981) pp 339-350; Bio-
chem. J. (1985) 226, pp 51-57; ibid. (1984) 217, pp 409-
417].
Furthermore, it is suggested that bilirubin forma-
tion and heme activity in mammalians are suppressed by
subcutaneous or intravenous injection [Clin. Pharmacol.
Ther., Vol. 39, pp 510-520 (1986)].
However, the hepatopathy-suppressing activity of
protoporphyrin IX-zinc(II) complex in oral administration
has not been revealed at all until now.
The present inventors have explored the possibility
of developing a drug which would be free of the ahove-
mentioned disadvantages and have potent antihepatopathic
action by oral administration.
Hepatopathy or liver disorder is epitomized by sever-
al characteristic clinical, biochemical, and histological
1 30~653
-- 3 --
findings such as elevation of hepatic enzymes in the
blood, such as glutamic-pyruvic transaminas~ (GPT), glu-
tamic-oxaloacetic transaminase (GOT), and alkaline phos-
phatase, elevation of serum bilirubin, necrosis of hepato-
cytes, and so on. Elevation of serum GPT and GOT levelsare observed in all hepatic disorder in common and the
determination of such hepatic enzyme activities and bil-
irubin levels in the blood has been utilized in the char-
aterization of hepatopathy and evaluation of its severity
and is routinely used in clinical laboratory test. There-
fore, the screening of prophylactic and therapeutic agentsfor hepatic disorder i5 usually conducted utilizing these
parameters.
For the experimental study of hepatic disorder,
a variety of hepatitis models have been developed. Among
them, models in rats or mice suffering from hepatic dis-
order induced by carbon tetrachloride are frequently
utilized. Hepatic disorder induced by carbon tetra-
chloride has been considered to be caused as the adminis-
tered carbon tetrachloride is transformed into the free
radical (-CC13) by cytochrome P-450 within the liver
cell and this free radical is bound to the cell membr~ne
protein of hepatocytes to strongly inhibit the cellular
activity or stimulate the peroxydation reaction of the
membrane lipid of its organelle, which results in altera-
tions in the membrane structure, thus damaying the hepato-
cytes.
`` 1 308653
-- 4
Using model animals suffering ~rom hepatic ~isor~er
induced by carbon tetrachloride, the present inventors
tested various porphyrin derivatives and ~ound that proto-
porphyrin IX-zinc~II) complex definitely inhibits the
elevation of GPT and GOT in the blood and also inhibits
increase of liver weight, exhibiting a potent amelio-
rating effect on the hepatic disorder.
Predicated on the above findings, one aspect of
the present invention is directed to an antihepatopathic
composition for oral administration which comprises proto-
porphyrin Ix-zn(II)complex in an effective amount for
suppressing the increases of glutamic-oxaloacetic trans-
aminase and glutamic-pyruvic transaminase in serum, and
a carrier.
A further aspect of the invention is directed to
a method for suppressing the increases of glutamic-oxalo-
acetic trans aminase and glutamic-pyruvic transaminase
in serum, which comprises administering orally an effec-
tive amount of protoporphyrin IX-Zn(II) complex to a
mammalian.
Protoporphyrin IX-zinc(II) complex according to
the invention can be easily synthesized from protoporphy-
rin IX by the known method.
In the present invention, protoporphyrin IX-zinc(II)
complex is administered orally. For the administration,
it can be provided in such dosage ~orms as powders, tab-
lets, pills, capsules, granules, suspensions, and so on.
1 308653
-- 5
The complex may be administered to a patient in
a dosage of 10 milligrams to 5 grams per day and prefer-
ably 10 milligrams to 1 gram, however, this dosage may
be decreased or increased according to the condition
of the patient. If ~esired, the complex may be adminis-
tered with other drugsO
Thus, the present invention provides an oral drug
which improves hepatic functions and suppresses hepatic
disorder, facilitating the prevention and treatment of
hepatopathy which has heretofore been difficult to manage.
The following examples and reference examples are
intended to illustrate the present invention, employing
mice as a model of mammalians, in further detail and
should by no means construed as limiting the scope of
the invention.
Exam~le 1
Method
Male ICR mice aged 4 weeks were used in groups of
lO animals. The test substance was suspended in 4%
aqueous gum arabic solution and the suspension was
administered by oral gavage once a day for 7 consecutive
~ays. Concurr~ntly with the last administration,
carbon tetrachloride in Z5~ olive oil was administered
subcutaneously in a volume of 2 ml/kg (0.5 ml/kg as
carbon tetrachlorida). The animals were then deprived
of food for ~4 hours, at the end of whlch time the
~.,,
..
1 30~653
hlood was drawn ~rom the abdominal aorta under ether
anesthesia. The blood was centrifuged (3,000 r.p.m.,
15 minutes) to separate the serum and GPT and GOT
activi-ties in the serum were determined (Reitmann-
Frankel ' 5 method). In addition, the liver was excised
and weighed.
To -the con-~rol group, 4~ aqueous gum arabic
solution was orally administered for 7 days and carbol~
tetrachloride-olive oil was subcutaneously administered.
To the normal group, 4~ aqueous gum arabic solution was
orally administered for 7 days and olive oil alone was
subcutaneously administered. As the control drug,
malotilate was used.
The results are shown below in the table.
- --~
Group Dosage Liver
Img/kg) GOT IKU) GPT ~KU) weight
.. . . . .. _ _ ... _
Normal 119+ 24 25~ 3 1.05i0.03
Control 5606~a876661+774*** 1.40~0.03
Zn-PP 203520+653*3175~358*** 1.39~0.03*
1002970~551*1970~172* 1.29~0.04
Malotilate 100 3245+552 4263~320 1.39i0.04
Note~ *: P<0.05, ***: P<0.001
KU: Karmen unit (the same applies to the follo~lng
tables)
Zn-pp: Protoporphyrin IX-Zn(II) complex
According to the above results, protoporphyrin IX-
Zn(II) complex oE the present invention dose-dependently
inhibited the elevation of serum GPT and GOT and also
- 1 3[)865~
inhibited the increase of liver weight. Fur~hermore,
the administration of the drug at 100 mg/kg caused signif-
icant decreases in GPT, GOT and liver weight. It was
thus made clear that the drug prevents carhon tetra-
chloride-induced hepatic disorder.
Reference _xam ~e 1
The test procedure of Example 1 was repeated except
that protoporphyrin IX-Sn(IV) complex was used as the
test substance. The xesults are shown in the following
table.
Group Dosage Liver
(mg/kg) GOT (KU) GPT (KU~ weight
. _ j . _ _ .
Normal 62+ 3 28+ 6 0.90+0.03
Control 2723+483 6364f 944 1.17+0.04
SII-PP 20 2839+398 7322+10~0 1.23+0.03
10~ 2489+222 6500+ 477 1.2~+0.04
15 Mote) Sn-pp: Protoporphyrin IX-Sn(IV1 complex
The above results indicate that protoporphyrin IX-
Sn(IV) complex has no prophylactic effect on carbon tetra-
chloride-induced hepatic disorder~
Reference Example 2
The test procedure of Example 1 was repeated
except that protoporphyri disodium was used as the test
substallce. The results are shown in the following
table,
1 30~65~
. .
GroupDosage Liver
(mg/kg) GOT (KU) GPT 5KUI weight
_ _ _ _ . _ _ . . _ _
Norlllal 51+4 28+ 2 ~.96~.05
- Col~trol 4771+726 1~958tl866 1.37~.05
PPN 20 3825~836 9400+22B7 1.30~0.04
100 3565-~84 8415~ 772 1.36+0.05
5~0 ~n2~713 9200~174~ 1~37~0.06
Note) PPN: Protoporphyrin dlsodlum
'rhe above results indicate that protoporphyn
disodium has little prophylactic effect on carbon
tetrachloride-induced hepat1c disorder.
The protoporphyrin compounds employed in the above
examples are prepared as shown in the following:
Refere~ E3~ e 3
Protoporphyrin IX-Zn(II) complex:
Protoporphyrin IX dimethyl ester (1.1g) was dissolved
in methylene chloride (200 ml~. The solution was refluxed
gently, a saturated solution of zinc acetate in methanol
(50 ml) was added thereto and refluxed for further 2 hours.
After being allowed to come to room temperature, ~he mixture
was washed three times each with 200 ml of water and dried
over anhydrous magnesium sulfate, and then solvent was
20 removed from the mixture by distillation. The residue
was subjected to alumina column chromatography employing
chloroform as an eluant to obtain a red fraction. Solvent
was removed from the fraction by distillation and the
remaining residue was recrystallized from the mixed solvent
25 f methylene chloride and me-thanol to obtain 800 mg of
protoporphyrin IX dimethylester-Zn(II) complex as reddish
purple crystals.
-"` 1 308653
g
The crystals were dissolved in pyridine ~250 ml),
1 N aqueous sodium hydroxide solution ~16 ml~ was added
thereto, and the mixture was refluxed for 2 hoursO After
the mixture was allowed to come to room temperature, sol-
vent was removed from the mixture by distillati~n andthe resulting residue was dissolved by adding water (50
ml) thereto. To the solution, a suitable amount of ace-tic
acid was added, and resulting precipitate was collected
by filtration, washed with water and dried to obtain 560
mg of protoporphyrin IX-Zn(II) complex as dark red
crystals.
Electronic spectrum (rmmax~ DMF): 419.8, 547, 584.2
IR (KBr, cm 1) 3450, 2910, 1710
NMR (DMF-d7, 8 ppm): 3.31 (t, 3H), 3.64 (s, 3H),
3.65 ~s, 3H), 3.78 ~s, 6H), 4.44 (t, 3H), 6.25 (dd, 2H),
8.53 (dd, lH), 10.22 (s, 1H), 10.25 (s, 2H)l 10.33 (s,
1H)
Protoporphyrin IX-Sn(IV) complex:
Protoporphyrin IX dimethyl ester (100 mg) was dis-
solved in methylene chloride (100 ml) and the solution
was refluxed gently. To -the solution, a saturated solution
of tin(II) acetate in methanol (20 ml) was added gradually
and the mixture was refluxed for further 2 hours. After being
allowed to come to room temperature, the mixture was washed
three times each with 100 ml of water and dried over anhy-
drous magnesium sulfate. Then, solvent was removed from
```` 1 308653
1 o --
the mixture by distillation and the residue was purified
by alumina ~Merck, active grade II-III) column chromatogra-
phy to obtain 80 mg of protoporphyrin dimethyl ester-Sn(IV)
complex.
The complex was dissolved in a solution of potassium
hydroxide (100 mg) in methanol, a small amoun~ of water
was added thereto and the mixed solution was refluxed
for 2 hours.
The resulting residue was dissolved by the addition of
water ((10 ml) and acetic acid (0.1 ml) was adcled to the
solution.
Resultant precipitate was collected by filtration,
washed
with water and dried to obtain 65 mg oE protoporphyrin
IX-Sn(IV) complex.
Electronic spectrum (~max~ DME) 416.5, 546, 584.5
IR (KBr, cm 1) 3450, 2910, 2850, 1705
NMR (~ppm, CF3COOD): 12.3 (s, 1H), 12.1 (s, lH~,
11.7 (s, 2H), 9.33 tdd, 2H), 7.23 (dd, 4H), 5.30 (br.t,
4H), 4.33 (br.s, 12H), 4.03 (br.t, 4H)
;J,~
